Efficacy and Safety of the Biosimilar IBI301 Plus Standard CHOP (I-CHOP) in Comparison With Rituximab Plus CHOP (R-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A Randomized, Double-Blind, Parallel-Group, Phase 3 Trial
Yuqin Song(Peking University), Xin Du(Guangdong Provincial People's Hospital), Yue-Rong Shuang(Jiangxi Provincial Cancer Hospital), Qingfeng Zou(Guangzhou Medical University), Shuye Wang(Harbin Medical University), Zheng Ge(Zhongda Hospital Southeast University), Xuelan Zuo(Zhongnan Hospital of Wuhan University), Ye Guo(Army Medical University), Liqun Zou(Sichuan University), Aibin Liang(Tongji University), Ying Xiang(Ministry of Education of the People's Republic of China), Wenhua Ran(Chongqing Three Gorges Central Hospital), Fangfang Lv(Fudan University Shanghai Cancer Center), Keshu Zhou(Zhengzhou University), Wei Sang(Xuzhou Medical College), Haiwen Huang(Second Affiliated Hospital of Soochow University), Ying Pang(Shanghai East Hospital), Wei Xu(Second Military Medical University), Shan Zeng(Central South University), Hongxia Yao(Hainan General Hospital), Da Gao(Inner Mongolia Medical University), Ming Hou(Qilu Hospital of Shandong University), Yang Shun-e(Xinjiang Medical University), Peng Liu(Xi'an Honghui Hospital), Mingzhi Zhang(Chinese Academy of Sciences), Jing Liu(Central South University), Lin Liu(The Affiliated Yongchuan Hospital of Chongqing Medical University), Li Y(Ya'an Polytechnic College), Hongyu Zhang(Huazhong Agricultural University), Zhen Cai(First Affiliated Hospital Zhejiang University), Jinying Lin(The People's Hospital of Guangxi Zhuang Autonomous Region), Hui Zhou(Hunan Cancer Hospital), Wei Li(Jilin University), Wei Liu(Henan University Huaihe Hospital and Huaihe Clinical Institute), Wei Zhang(Chinese Academy of Medical Sciences & Peking Union Medical College), Jifeng Feng(Zhejiang Cancer Hospital), Zhendong Chen(University of Cologne), Huaqing Wang(Beijing University of Technology), Yongqing Cao(The First Hospital of Changsha), Zonghong Shao(Tianjin Medical University General Hospital), Wei Yang(China Medical University), Hao Xu(Affiliated Hospital of North Sichuan Medical College), Ruixiang Xia(Anhui Medical University), Jianfeng Zhou(Huazhong University of Science and Technology), Junxun Ma(Chinese People's Liberation Army), Ru Feng(Chinese Academy of Medical Sciences & Peking Union Medical College), Qingyuan Zhang(Sun Yat-sen University), Meifang Zheng, Lin Wang(The Synergetic Innovation Center for Advanced Materials), Huilai Zhang(Shanxi Medical University)
Cited by 19
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: a cross-sectional study
|The Lancet Public Health|2020|1.8k
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
|The Lancet Oncology|2015|1.6k
The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder
|Neuroscience & Biobehavioral Reviews|2021|1.4k